Redeye: Moberg Pharma - Making good progress
The development in the OTC business was solid in 1Q18 and beat our expectations in almost every aspect. With a positive development in 1Q18 and a stronger USD, we raise our forecasts and our fair value to SEK 64 (62).
Read more in the Research Update by Klas Palin: https://goo.gl/nEcvL2
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/